Andreas Schneeweiß
A5089392438- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- Cancer Diagnosis and Treatment
- Caveolin-1 and cellular processes
- Neutropenia and Cancer Infections
- MicroRNA in disease regulation
National Center for Tumor Diseases
2016-2025
Heidelberg University
2016-2025
University Hospital Heidelberg
2016-2025
German Cancer Research Center
2015-2025
Cancer Clinic
2025
NSABP Foundation
2025
National Cancer Institute
2025
Helios Hospital Berlin-Buch
2007-2025
Frauenklinik Heidelberg
2012-2024
DKFZ-ZMBH Alliance
2006-2024
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy pertuzumab, trastuzumab, and docetaxel, as compared placebo, docetaxel. Overall pertuzumab in an interim analysis without the median being reached. We report final prespecified overall results a follow-up of 50 months.We randomly assigned who had not received previous chemotherapy or anti-HER2 their...
The efficacy and safety of combining bevacizumab (7.5 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.Patients (N = 736) were randomly assigned to 100 mg/m(2) plus either placebo 7.5 mg/kg every 3 weeks. primary end point progression-free survival (PFS); secondary points included best overall response, duration...
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or the miRNA binding sites may affect dependent gene expression regulation, which has been implicated various cancers, including breast cancer, and alter individual susceptibility to cancer. We investigated associations between related SNPs cancer risk. First we evaluated 2,196 a case-control study combining nine genome wide association studies (GWAS). Second, further 42 with suggestive evidence for using...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Data for multiple common susceptibility alleles breast cancer may be combined to identify women at different levels of risk. Such stratification could guide preventive and screening strategies. However, empirical evidence genetic risk is lacking. We investigated the value using 77 cancer-associated single nucleotide polymorphisms (SNPs) stratification, in a study 33 673 cases 381 control European origin. tested all possible pair-wise multiplicative interactions constructed 77-SNP polygenic...
We investigated disease-free survival (DFS) and overall (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer.We treated 2,072 two cycles of docetaxel, doxorubicin, cyclophosphamide (TAC) randomly assigned responders to four (n = 704) or six 686) additional TAC cycles, nonresponders 321) vinorelbine capecitabine (NX; n 301) before surgery.DFS was longer receiving × 8 than those 6 (hazard ratio [HR], 0.78; 95% CI, 0.62 0.97; P .026), TAC-NX (HR, 0.59; 0.49...
Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of cancer. Our randomized phase II study investigated cisplatin with or without cetuximab this setting.Patients who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 schedule to receive six cycles plus alone. Patients receiving alone could switch disease progression. The primary end point was overall response rate (ORR)....
•Final OS data from IMpassion130 (A + nP in metastatic triple-negative breast cancer) agree with prior interim analyses.•OS benefit A versus P the ITT population was not statistically significant, precluding further testing.•Exploratory formally tested showed clinically meaningful for PD-L1 IC-positive population.•Three-year rates were 35.8% 22.2% nP.•No new safety signals seen longer follow-up; adverse events consistent those known each drug. BackgroundGuidelines recommend atezolizumab plus...
<h3>Importance</h3> The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether<i>BRCA1</i>and<i>BRCA2</i>germline mutation status affects treatment outcome remains elusive. <h3>Objective</h3> To determine whether<i>BRCA1</i>and<i>BRCA2</i>germline therapy TNBC. <h3>Design, Setting,...